Who Supplies Calcium to India from SWITZERLAND

To import finished pharmaceutical formulations containing calcium into India, foreign manufacturers must obtain an Import Registration Certificate and an Import License from the Central Drugs Standard Control Organization (CDSCO). The application process involves submitting detailed product information, including composition, manufacturing process, and stability data. The CDSCO evaluates the safety, efficacy, and quality of the product before granting approval. The timeline for import drug registration varies but typically ranges from 6 to 12 months. For formulations under HS Code 30049099, compliance with the Drugs and Cosmetics Act, 1940, and associated rules is mandatory.

Imported finished pharmaceutical formulations containing calcium must undergo quality testing at CDSCO-approved laboratories. Batch-wise testing is required, with each batch accompanied by a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, adhering to ICH Zone IV guidelines, must be provided to demonstrate the product's shelf-life under Indian climatic conditions. Upon arrival, customs drug inspectors conduct port inspections to verify compliance with regulatory standards.

Between 2024 and 2026, the CDSCO has implemented stricter regulations for importing pharmaceutical products, including mandatory import registration and licensing. The introduction of the Production Linked Incentive (PLI) scheme has incentivized domestic manufacturing, potentially impacting the volume of finished formulation imports. Bilateral agreements between India and Switzerland have facilitated smoother trade relations, but no specific exemptions or preferential rates have been established for Swiss-origin products.

India imports finished calcium formulations to meet the demand for patented and branded products, specialized dosage forms, and formulations not produced domestically. The domestic market for calcium formulations is substantial, with a total export value of $895.2 million across 996 exporters to 184 countries. However, domestic production may not fulfill all therapeutic needs, leading to reliance on imports to bridge the gap.

The import duty structure for finished pharmaceutical formulations under HS Code 30049099 includes a Basic Customs Duty (BCD) of 10%, an Integrated Goods and Services Tax (IGST) of 12%, and a Social Welfare Surcharge (SWS) of 10%. This results in a total landed duty of approximately 17.10%. There are no additional duties such as Anti-Dumping Duty or exemptions for Swiss-origin products.

Switzerland's pharmaceutical industry is renowned for high-quality standards, innovative formulations, and adherence to stringent regulatory requirements. Swiss manufacturers offer patented calcium formulations and specialized dosage forms that may not be available from other suppliers. While countries like China, Germany, and the United States also export calcium formulations to India, Switzerland's reputation for quality and reliability provides a competitive advantage in the Indian market.

India imports calcium formulations from Switzerland due to the availability of patented products, specialized dosage forms, and formulations that are not produced domestically. Swiss manufacturers offer high-quality products that meet international standards, fulfilling specific therapeutic needs in the Indian market.

Compared to other suppliers like China, Germany, and the United States, Switzerland offers a competitive advantage in terms of product quality, regulatory compliance, and reliability. While other countries may offer lower prices, Swiss products are often preferred for their superior quality and adherence to stringent manufacturing practices.

Potential risks for Indian importers include single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. To mitigate these risks, importers should consider diversifying their supplier base, maintaining adequate inventory levels, and establishing contingency plans for supply chain disruptions.

1. 1Dual-Sourcing: Engage multiple suppliers to reduce dependency on a single source.
2. 2Inventory Planning: Maintain buffer stocks to manage supply chain disruptions.
3. 3Payment Terms: Negotiate favorable terms such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP).
4. 4Minimum Order Quantities (MOQs): Align order quantities with market demand to optimize inventory costs.
5. 5Supplier Qualification: Conduct thorough due diligence to ensure suppliers meet quality and regulatory standards.

1. 1Obtain Importer Exporter Code (IEC): Register with the Directorate General of Foreign Trade (DGFT).
2. 2Apply for CDSCO Registration Certificate: Submit Form 40/41 to CDSCO with required product details.
3. 3Secure Import License: Obtain a valid import license from CDSCO.
4. 4No Objection Certificate (NOC): If applicable, obtain NOC from the Ministry of Health and Family Welfare.
5. 5Engage Customs Broker: Appoint a licensed Customs House Agent (CHA) for clearance procedures.
6. 6Advance Ruling: Seek advance ruling for HS Code 30049099 to confirm classification and duty rates.

1. 1Certificate of Analysis (CoA): Confirming product quality and compliance.
2. 2Certificate of Pharmaceutical Product (CoPP): Indicating GMP compliance.
3. 3Good Manufacturing Practice (GMP) Certificate: Issued by the competent authority.
4. 4Drug Master File (DMF): Providing detailed manufacturing information.
5. 5Stability Data: Adhering to ICH Zone IVa/IVb guidelines.
6. 6Free Sale Certificate: Indicating product availability in the country of origin.
7. 7Manufacturer Authorization: Authorizing the importer to distribute the product.

Upon arrival, CDSCO port inspectors collect samples for mandatory batch testing. The process includes sample collection, testing for compliance with Indian Pharmac